Company · founded 2014
Molecular Theranostics (United States)
Cleveland, United States · mtheranostics.com
- Citations, last 5 years
- 109
- Works, last 5 years
- 10
- h-index
- 12
- Scientists listed
- 0
- Grants since 2016
- 20
Grants received
2024–2026 · research · R43
A peptide targeted fluorescence probe for precision surgery of head and neck cancer
Ryan Christopher Hall · Molecular Theranostics (United States) · funded by National Institutes of Health
2023–2024 · research · R43
Formulation and pharmacokinetics of subcutaneous administration of deferiprone for prevention of chronic heart failure following hemorrhagic myocardial infarction.
Robert E Finney · Molecular Theranostics (United States) · funded by National Institutes of Health
2023–2025 · research · R43
Development of peptide drug conjugates for cancer therapy
Ryan Christopher Hall · Molecular Theranostics (United States) · funded by National Institutes of Health
2022–2025 · research · R44
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer
Songqi Gao · Molecular Theranostics (United States) · funded by National Institutes of Health
2022–2024 · research · R44
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer
Yajuan Li · Molecular Theranostics (United States) · funded by National Institutes of Health
2022–2025 · research · R43
Sub-100 nm and scalable self-therapeutic nanoparticles to target autophagy in pancreatic cancer
Tzu-Yin Lin · Molecular Theranostics (United States) · funded by National Institutes of Health
2021–2023 · grant · Standard Grant
SBIR Phase I: Development of a Lung Health Diagnostic Test for COPD and Prognosis-Based Early Intervention
Neeraj Vij · Molecular Theranostics (United States) · funded by National Science Foundation
2019–2021 · research · R43
Transformable nano-theranostics for image-guided interventions in head and neck squamous cell carcinoma
Tzu-Yin Lin · Molecular Theranostics (United States) · funded by National Institutes of Health
2019–2026 · research · R44
Transformable Theranostics for imaging-guided interventions in head and neck squamous cell carcinoma
Tzu-Yin Lin · Molecular Theranostics (United States) · funded by National Institutes of Health
2019–2025 · research · R44
Transformable Theranostics for imaging-guided interventions in head and neck squamous cell carcinoma
Tzu-Yin Lin · Molecular Theranostics (United States) · funded by National Institutes of Health
2019–2025 · research · R44
Transformable Theranostics for imaging-guided interventions in head and neck squamous cell carcinoma
Tzu-Yin Lin · Molecular Theranostics (United States) · funded by National Institutes of Health
2018–2020 · research · R43
Ninja Theranostics for overcoming the drug delivery barriers to pediatric brain tumor
Paul Thomas Henderson · Molecular Theranostics (United States) · funded by National Institutes of Health
2018–2019 · research · R44
Extremely long tumor retention, on-demand releasing Nano-Taxel for eradicating ovarian cancers
Paul Thomas Henderson · Molecular Theranostics (United States) · funded by National Institutes of Health
2018–2024 · research · R44
Extremely long tumor retention, on-demand releasing Nano-Taxel for eradicating ovarian cancers
Tzu-Yin Lin · Molecular Theranostics (United States) · funded by National Institutes of Health
2018–2021 · research · R44
Extremely long tumor retention, on-demand releasing Nano-Taxel for eradicating ovarian cancers
Tzu-Yin Lin · Molecular Theranostics (United States) · funded by National Institutes of Health
2017 · research · R43
iCardioTox Profiler - Developing a Novel In Vitro Assay to Assess Cardiotoxicity Using a Panel of Patient-derived Cardiomyocytes
Kevin J Kim · Molecular Theranostics (United States) · funded by National Institutes of Health
2016 · grant · Standard Grant
SBIR Phase I: Developing a Novel In Vitro Assay Using Patient-derived Cardiomyocytes To Screen for Drugs To Treat Hypertrophic Cardiomyopathy
Jason Lam · Molecular Theranostics (United States) · funded by National Science Foundation
2015–2021 · research · R44
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer.
Yajuan Li · Molecular Theranostics (United States) · funded by National Institutes of Health
2015–2020 · research · R44
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer.
Yajuan Li · Molecular Theranostics (United States) · funded by National Institutes of Health
2015–2020 · research · R44
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer.
Yajuan Li · Molecular Theranostics (United States) · funded by National Institutes of Health
